Welcome to Circio. My name is Erik Digman Wiklund. I am the CEO. Today we are presenting our First Half-year results, as well as an update on our circVec R&D program. Together with me, I have CFO Lubor Gaal, as well as Thomas Hansen, CTO. I will begin with a short highlights session, as well as an update on relevant market conditions. Importantly, during the first half of the year, we've been operating under funds raised in the warrant exercise end of 2024, as well as the Atlas facility. This This has enabled us to have a stable cash flow into the company. We've also extended the financing commitment with Atlas. This secures capital to fund our operations until the end of the year, with an option for further extensions into 2026. On business development, we have been very active. We entered seven R&D collaborations during the first half of the year, and Lubor will come back to these in his presentation. Importantly, we made substantial progress on our circVec platform. We've now shown convincing strong proof of concept in vivo, both with our AAV circVec program, as well as in vivo CAR delivering DNA circVec constructs into the spleen. Thomas will be covering these programs in his presentation. I'd also like to bring your attention to a publication we had in Nature Reviews Genetics by our scientists in the beginning of 2025. This is a very comprehensive review of the circular RNA space and their therapeutic potential. Anyone interested in circular RNA, I highly recommend you tune in and read that review in Nature. In addition, we presented our data at ASGCT in New Orleans in May. This is the preeminent global leading cell and gene therapy conference and an excellent platform for Circio to showcase our currently quite compelling data. We are, as a lead, focusing on gene therapy with AAVs as our main prioritized program at the moment. The first gene therapy was approved in 2017, and already now we have seven approved AAV gene therapies. When you hear about gene therapy, the AAV vector is really the workhorse of all of these. There are some major challenges with AAV. They require really high dose levels because they're not particularly active or potent when injected into humans. That high dose level drives up toxicity and it drives up the manufacturing costs. This is making many of these AAVs struggle commercially for those reasons. There has been substantial news in this field in the past few months. There was an issue with the Danon disease AAV program by a company called Rocket Pharmaceuticals, where there was a patient death in a clinical trial, probably driven by the high dosage level of the AAV. It is an area where the AAV is active, but the toxicity is very severe in the patient. For that reason, the FDA required a clinical hold, so the trial had to stop. There have also been substantial discussions around a company called Sarepta. This is one of the leading gene therapy companies in the world. They had to pause trials in LGMD muscular dystrophy, again for safety reasons. This is where Circio comes in, and our circVec technology can really help solve some of the key challenges. We have data now showing that you can improve the activity level of an AAV gene therapy by 10 to 40-fold if you switch to our circVec-based expression. If you can reduce the dose by tenfold, that would be massive for this space. It would reduce the toxicity level, probably also reduce the cost, and maybe eliminate the need for co-administration of immune suppressant medications. Based on what we're seeing today, we believe that in the future, everyone is going to switch to circ RNA-based expression because it's looking like it's simply more potent than the way it is done today. Thomas will come back to this and explain in more detail. Our lead program, gene therapy, enhancing AAV vectors, and we're looking at multiple disease areas in this space. In parallel, as we've communicated before, we're also pursuing a cell therapy program with the aim of developing an in vivo CAR approach utilizing circlic DNA vectors. In this case, we're not dealing with viral AAV vectors. We're dealing with a DNA format, which is re-dosable and enables the possibility of a more durable in vivo CAR cell therapy. With that, I hand over to Thomas. Thank you, Erik. Thank you all for tuning in. I'm a little taller than Erik, as you can see, so I need to step down a bit. Thank you all for tuning in. I'm very pleased to give you this R&D update. We have some very interesting data to share with you this morning. Before we get to the recent data, I'm just going to bring us up to the same page. Just to remind you all what we are doing at Circio, that is we are developing our circVec platform. That is basically a DNA cassette that when it enters the cell, it uses the host cell machinery to produce circular RNA. Those circular RNAs are then designed in a manner that they will engage in CAP independent translation and produce your protein of interest. The reason we believe that this circular intermediate is a good approach is because the circular RNA is extremely stable within cells, much more stable than mRNA. As a consequence, you see longer expression. More importantly, in gene therapy, you get an accumulation of RNA within cells. You can sort of imagine you get constant production of circular RNA. They'll hang around for a long time. The steady state level of the circular RNA in the end is much higher than the mRNA. In return, you get higher protein expression per DNA copy number, basically. It's a more effective way of producing proteins in cells. That cassette, we can simply take that and put it into a vector system. Of course, we're working a lot with AAV vectors because that is still the most well-described system for gene therapy. Instead of expressing an mRNA from the AAV, we put in our circVec cassette. As a consequence, the AAV will then produce the circular RNA in cells. You'll get those benefits that I just described from the circular RNA, namely that enhanced expression of your protein, which will be very important in gene therapy, as Erik just mentioned. You get a better, more effective expression of your therapeutic protein. Before summer, we already were very excited about our AAV data. What we did there was we expressed our circVec using a heart-specific promoter, which stimulates expression in heart specifically. We compared how circVec w ould compare to an nVec, the mRNA, the conventional benchmark in terms of expression. If you look across the mouse and you measure how much luminescence, we expressed this reporter gene that's easy to monitor over time, we see a tremendous increase from circVec, r anging from 9x improvement in the high dose to 35x improvement in the low dose, which was a significant improvement. Something that was a little fly in the ointment back then is that we've been working on the Generation 3 in vitro. We thought that was a promising new design for circVec expression. Unfortunately, in this experiment at least, we did not see that benefit in vivo, as you can see if you compare the circVec 2.0 to 3.0. We were not ready to give up on the Generation 3, even though that data did not translate fully from the in vitro to the in vivo data. We kept modifying the Generation 3 circVecs. We tried multiple different things and came up with this circVec 3.2, as we call it. This is all based on some elements that we positioned at the very end of the cassette, as is depicted to the right. Interestingly, when we then use that in the same setting as before, namely injecting the AAV systemically and monitoring the luminescence in mice over time, we see this remarkable increase in expression if you compare the different circVec generations. Here we now have 32x improvement over MVEC and 3x improvement over the previous circVec generation based on the whole body luminescence of the mouse. That was very exciting data that we were able to gather here over the summer. It gets even better because when we sort of monitor the expression in the heart specifically, you can take the profile of expression and look at the heart region specifically. You see to the left, it's basically how the signal of the circVec 3.2 is most notable for that vector because it drives up expression so immensely in the heart. If you then quantify that area under the curve, you actually reach more than 40x improvement over MVEC in the heart specifically. I would say that, mildly said, that is a massive improvement that we're now observing specifically in the heart. Of course, going back to what Erik mentioned with the Rocket Pharmaceuticals in Danone disease, that is a disease that is affecting the heart. That is where you basically want as effective heart expression of the missing protein, which in Danone disease is called LAMPP2. If we are able to reduce dosing 40-fold in Danone disease, I think all those toxicity issues that Rocket Pharmaceuticals is currently facing would probably be less problematic. This is something that we are very interested in pursuing in more detail going forward. That's extremely exciting, but that's not all. We have also been very interested in characterizing circVec performance in ophthalmology. That is sort of in the eye. What you can do here is you can actually inject AAV vectors intravitreally, as it's called. You basically inject it in the eye. Then, similar to what you saw before, you can monitor luminescence over time. Very encouragingly, we also see a substantial increase in circVec expression in this setting. I'll just point your attention to the fact that this is not even the 3.2. This is an older circVec that carries a ubiquitous promoter that allows expression in the eye. We are definitely pursuing this and pursuing this further because a 15x improvement with circVec 2.0 in this setting is very encouraging. There are a lot of rare diseases where AAV technology would be very, very suitable in such a setting for different ophthalmology indications. That is very, very encouraging for the AAV gene therapy using circVec. That basically brings me to the summary. What I've shown you now is that we're able to outperform MVEC significantly depending on the context. The circVec cassette is more than tenfold, even more than 40-fold in the heart specifically. Critically, we see a circVec advantage across different settings. We not only see that in the heart, but we also see it in the eye. That is basically using different promoters, in this case also using different AAV capsids. Clearly, this not only sort of validates circVec as a versatile platform, but it also is very encouraging to see that circVec specifically, but I think also circVec RNA in general, is a very promising technology in gene therapy, namely because it can drive up protein expression much more effectively than an mRNA equivalent. Moreover, we've seen now that the most recent 3.2 design actually improves expression by roughly threefold in the heart. That's very encouraging as well. Coming back to, for instance, some of the toxicity that's been currently observed in the AAV field, if we are able to reduce dosing just by tenfold, let's say, without losing clinical benefit, that would be a game changer in gene therapy because the safety profile would be different, reduce toxicity, much safer for the patient. I think that will definitely be a new avenue for AAV gene therapy overall. We are very, very excited about this development at Circio. We keep pushing forward. We still, for our gene therapy pipelines, have a huge focus on heart and muscle still, specifically with focusing on heart, given the current data. We have some ongoing studies in the CNS and in the eye, as I just showed you. We will, of course, also deploy the most recent circVec designs in those settings and see what improvements do we observe and what benefits are we seeing from the most recent circVec designs. We are gearing up now to start looking into more therapeutic avenues, looking into what specific indication would be a good fit for circVec. I mentioned Danon disease, where Rocket Pharmaceuticals are struggling. This seems to be a good fit. This is something we are looking into in more detail. We are looking at different ophthalmology indications, given the data that we can likely get at least 15x improved expression. There are a lot of avenues that we are currently evaluating, looking into CROs that have the relevant mouse models and designing the constructs that would be relevant for the given indication. This is all ongoing. We hope to be able to initiate some of these therapeutic sort of relevant studies by the end of the year. We are not touching much upon that in this webcast, but we also have a program on in vivo CAR. Here we are looking in, this is a non-viral approach. This is not AAV based, but this is where we want to target the spleen or target T cells specifically using some type of delivery technology, likely an LNP that would carry the circVec vector into the target cells. We are discussing this with multiple different partners and try to identify the best path forward here because, as you've seen in the past, we have some very encouraging data with circVec expression and robust circVec expression in the spleen. In parallel in the lab here in Stockholm, we are, of course, also pushing forward towards an even better circVec cassette. I would be surprised if we reached the ceiling now. I think we can still improve on circVec. This is going on in parallel, namely producing circVec Generation 4. Exciting times to be employed at Circio. I hope you've enjoyed this R&D update. Now I'll like to hand it over to Lubor, who will give you the corporate update. Thanks, Thomas. Very exciting. It will be difficult to follow this exciting presentation about these really interesting results. I will give you an overview of our financial activities and business development activities over the last six months and our plans going forward. We started the year in a very good position following the warrant exercise and the private placement in December of 2024. As you all know, the warrants were oversubscribed, which showed a strong interest in our technology. We were able to finance the first half of 2025 on a combination of that warrant exercise plus so-called selected transfers from Atlas Capital Markets. Of course, we had ongoing discussions with investors during that time. I will give an update on that later. Very importantly, we were able to extend our runway. The finance commitment with Atlas, which ended in June, was extended. We can now say that we have safe operation until the end of 2025. This is, of course, possible because we continue to control our costs tightly. I will talk a little bit more about the impact in the financial figures on the next slide. Very importantly, I think we have to compare ourselves to where we were about 12 months ago, same time last year. We reduced the outstanding bonds from $35 million to less than $10 million. We reduced the financial risk. We've stacked our cap table with new investors who've taken strong positions in Circio. Also, of course, with some of our major shareholders increasing their positions. We have a much stronger cap table now than last year. Importantly for us, of course, as you just heard from Thomas, we made great progress with our technology. We have really validated the technology in different tissues and different technologies, different aspects. We're now very, very confident about the benefit of this technology. Together, we feel like we're in a much stronger position at Circio compared to where we were 12 months ago. We have a much stronger data package, a stronger technical program, and we have a much stronger financial position. Let me walk you through the numbers of the first half of 2025. They're very much in line with the six months periods previously in 2024. As you can see, we continue, of course, to invest in R&D. This is very important. As you can see from the presentation of Thomas, we need to run more experiments to test technology, different aspects of technologies. We have found a very cost-efficient way to do that. We actually are very productive and can generate a lot of results based on a relatively modest budget. This is also only possible because we have a very efficient R&D team. Our team are, of course, the leaders in circular RNA. We have the most experienced people who can really apply this technology in the settings. We'll continue to operate with a small team very efficiently. As we said, we have to control our costs. The operating expenses, we keep to as low as possible. There are certain expenses as a public company, of course, that we have to have. We'll continue to operate as small as possible. As you can see on the total operating expenses, we've been very stable compared to the last six months. You can now say that we're operating on a budget of less than NOK 4 million per month. We can continue on this basis going forward. We would like to increase our activities if possible. On the financial items, just quickly highlighting, the difference in the numbers between 2024 and 2025 is that in 2024, we recognized the waiver of the ONCOS- 102 R&D loans that we received much earlier. Otherwise, the operating expenses rectified financial expenses that we have because of the Atlas Capital Markets agreement. We want to draw, yes, the net cash at the end of the period is quite low, but this is low by design. We, as we said, will call transfers from Atlas Capital Markets only on an as-needed basis. We want to purposely keep the money quite low right now. What are we doing in terms of financing? Based on the new data that we just generated, we're going to continue our discussion with investors. We are quite confident that this new data will generate a lot of interest from investors. We also need to say that the market conditions remain challenging, not just for biotech companies, but globally. You're all aware of what's going on in the world. That also has an impact on the behavior or decisions of investors in biotech companies. What we have seen over the last six months is that while we do get quite a lot of interest, we also get in discussion a moving of the goalposts with some of these investors who keep then demanding more and more data. With the new data package, we're quite confident that we can address many of those questions. We're also, of course, quite happy with our relationship with Atlas. We were able to negotiate a financing commitment until the end of 2025 based on the strong performance in the first half of this year. We have a good relationship with Atlas, and we continue to explore different options of working with Atlas Capital and, of course, raising financing. We are grateful to Atlas Capital Markets for giving us reliable access to capital during tough market conditions. Of course, we're looking elsewhere to generate new funding. Business development, as Erik was already saying, we continue to establish strong technology collaboration. I will give into more details on the next slide. We will leverage the new data that Thomas just presented in talking to gene therapy companies, which we then hopefully can leverage into early-stage technology collaborations. We continue to monetize our technology in non-core or complex areas in collaboration with other companies. I will give an example on the next slide. Let me give you an update. We are showing here five business development collaborations, but the title says seven. That's because two of them remain confidential. What do you have these technology collaborations in common? Our circVec cassette needs to be delivered to the right tissue, to the right cells in the body. We need to do that with another technology. We always need to combine our circVec cassette with another technology, either with a vector, a virus, or an LNP. These companies, Entrostratus Neuroregion, have different delivery technologies that we need. We need to do these combinations and need to test which combination works best for us. Some of these collaborations are complementary, and some of them are competing with each other. This means we can have different delivery technology to go to different tissues in the body, or we just have different formulations of the same class of delivery technology. We don't expect all of these collaborations to work out, or even if they do work out, we will compare them versus each other. We will expect to take the best technology forward for the different purposes. I won't go into too much detail here. If there is interest in learning more about them, of course, send us an email, and we can explain in more detail. Like we're just saying, quite exciting about having established so many collaborations in such a short period of time. I do want to highlight a little bit the collaboration we have with Lonza, which is that one of what says is a novel use. As you, as Thomas has said or shown, our technology is extremely efficient in expressing proteins. Expressing proteins, of course, is very important in a lot of the manufacturing of therapeutics, of antibodies, and other proteins. What we're trying to hope with this technology or with this collaboration, Lonza is one of the, or maybe the imminent manufacturer of biologics in the world. They have a proprietary technology or expression system. We are working together with them and seeing how our technology could benefit in their system. We're quite excited if that leads to positive results. Of course, that could be an additional benefit to leverage our technology in areas where we would not be active ourselves. With that, let me wrap up. What are the next milestones on BD activities? As I said, we're going to have ongoing discussions with AAV gene therapy companies where we're going to go and talk to more companies of trying to get them interested in our technology and test them in-house. We will be pursuing or are pursuing discussions with cell therapy companies that Thomas alluded to before and leverage the technology in that area as well. Of course, as I said, we are working with the existing companies in delivering the results. We expect to have some results later this year, but we may not be announcing all of these results because sometimes for competitive or IP reasons, but also because we may not decide to go forward with certain technologies and then focus on some others. Do not expect to hear anything soon, but there will be a lot of activities ongoing. With that, I hand over to Erik. Thank you, Lubor. To summarize, take-home messages, we have a platform here in circVec that delivers unprecedented durability and protein expression advantage over conventional mRNA-based expression systems. This is versatile in that it applies both to viral vectors and non-viral vectors. Focus for us now is deploying that in enhancing AAV gene therapy to enable reduced dosing and more safe gene therapies in the future, and LNP or other delivery technologies to enable DNA delivery to in vivo CAR approaches. This technology has true platform potential. It's a first-in-class industry-leading circular expression system. We're not aware of any other companies or academics that have a circular expression system that performs as well as circVec does. We have multiple opportunities in several disease areas, and we plan to both be partnering and develop programs in-house. With that, we conclude the presentation part of this report, and we can move to Q&A. We have received several questions. Maybe, Lubor, you want to start with finance and business development? Sure, happy to. We received the questions on our cost base. We operated on NOK 4 million per month as a budget for the past year and a half. Are you able to extend this, and do you expect the same cost basis going forward? Absolutely. Now, we have our very well-established operations. Clearly, we need to operate under the $4 million budget because that's the transfers that we can draw from Atlas. We found a way to be very efficient in our operation, and we can maintain this level for the foreseeable future. As I said, of course, it does come at a cost. I mean, of course, we cannot do too much. We have to operate efficiently with a small team. Of course, if we had more money, we could do more. We could have faster progress. We can definitely operate at this level going forward. There's no problem. We received several questions on business development. You mentioned, Lubor, that there are ongoing discussions on the AAV gene therapy. Could you elaborate on the timeline and what kind of deal you would expect? Deals don't happen overnight. Sometimes even when companies are interested in working together, it does take time to negotiate contracts because these collaborations can be quite extensive and complex. Contract negotiation can take months, unfortunately. We would like to enter this collaboration, of course, as soon as possible. We have to be cognizant that pharmaceutical companies or other companies take their time in making these decisions and also in negotiating these contracts. Like you said, we have ongoing discussions. We are confident that some of them will lead to a successful completion in this year. It'd be very difficult for me to predict the month. You can be assured that we're working as fast as possible to have them signed or established as soon as possible. We're very confident. We're very encouraged by the discussions we have ongoing. We get the right signals. We're very confident that this will happen this year. We will now also be going out there and marketing these new results, which I think are substantially stronger than what we had before. The new results will definitely help in our discussions. We can already see that in some of the conversations that we're having. This definitely will be a much better discussion going forward. We have a few technical questions as well. Maybe I invite Thomas to take those. Sure. On the Generation 4 circVec, Thomas, what kind of advantage could you expect? Is this in any way delaying or impacting the advancement of the circVec program in terms of therapeutic programs? Yeah, we are currently characterizing the new generation of Circuit vectors in the lab. We have a very strong R&D team here in Stockholm working hard to namely build and optimize Circuit cassettes. I think now we are, I mean, I think it's too early to say, but I think we hope to see at least a significant improvement on top of 3.2. Let's see how that translates into a mouse. We can never know with certainty how that looks. We are very encouraged already now by the 4.0. Yeah, a little early to say. Regarding the development of a therapeutic program, I think this is something that could easily go in parallel. This is not something that necessarily will pause or change the pace by which we develop the Circuit 4.0. A lot of these in vivo experiments are, we are not doing that in-house. This is in many cases done by either an animal facility here at KI or by other CROs. That work can definitely go on in parallel. I think it's also interesting now with the data at hand. I think we are ready now to embark on some therapeutic proteins and do these mouse models because that is, of course, a little bit more expensive. It takes longer time. It's more complex to interpret the data. I think now the technology is ready to fully dig in. I think we will, as mentioned, probably look close at Danone disease and different ophthalmology indications to start with. Hopefully, as I mentioned, we will aim and hope to initiate some of that this year. Hope that covers. Thank you, Thomas. We also had some questions around the disease models and timing, but I think you covered that in your answer. Given the data that has been produced, is this impacting your thinking around which areas to prioritize and what may be your lead indication? Yes, of course, we are following the data. Clearly now, the strongest data we have is in heart. 44x improved heart expression from circVec compared to MVEC. Clearly, this is something we are looking at. I think that, you know, given the data, that's where Circuit has the strongest profile. Eye data is also looking extremely promising. I think these, as mentioned, these two avenues are something we are looking at in more detail. Identifying CROs that have the suitable know-how and mouse models to help us with these particular mouse models is ongoing work. To stress, EyeDect is, of course, with circVec 3.2. Yes. The circVec Generation 2 is actually performing better in Eye than it did in the heart. We are very curious to see how our 3.2 variant will perform in Eye when we get around to do that experiment. Yes, this is something that we are setting up as we speak. Thank you, Thomas. Thank you. A couple of more questions we've received that I can cover. There is a question around Certest. This is a collaboration partner we have with an LNP technology that we use to deliver to the spleen. There is some concern we've heard that they have done a deal with a company called Emer and whether that impacts Circio. I'd like to stress that Amrivax is doing something completely different to us. That's a circular in vitro transcribed circular RNA company. Remember, we are making DNA and viral vectors. Certest and Amrivax have entered an exclusive relationship when it comes to the delivery of circular RNA. This is different to what we're doing. It has no impact whatsoever on our programs, which are DNA delivery when it comes to that collaboration with Certest. There is also interest and questions around the TG01 program and when we can expect data from that. These are clinical trials. We have two ongoing clinical trials with TG01, one at Georgetown University in the U.S., and the second one is in Norway. The Norwegian trial, we published data in June of this year, which looks very encouraging. That's a good start. That trial should be fully enrolled, hopefully by the end of the year, and then data will be coming out next year. For Georgetown, we have less insight. These studies are investigator-initiated. It's not controlled by Circio how they progress when data is reviewed. I would expect that during this year, we should be able to get updates and probably presentations at a suitable conference next year. There is also interest still in IO and questions around that. I can say that we still have a dialogue with IOVaxis. They are trying to set up clinical studies in China. Due to financial market conditions, they so far have been unable to finance those efforts. Lastly, around our in vivo CAR program, we received a question that there are many of these programs now in development. We saw multiple acquisitions by Big Pharma in the space, but they're all looking more or less the same. What is the Circio differentiation? I think this is a very important question. As far as we know, most or all of the in vivo CAR programs are either based on delivering mRNA or synthetic circular RNA. That's proven very effective in NHPs, so in monkeys. The first programs are now moving into clinical trials. That would be very exciting to see how it progresses. What's important is that when you use RNA, you get really short expression windows. With mRNA, one to two days, and then the expression is gone. With a circular RNA, synthetic circular RNA, that is extended to maybe one week, but it's still transient. What we have shown with our spleen delivery data is that we can express in the spleen, specifically in B and T cells, for three months or more. It's a completely different temporal window. We can get much more durability because we're expressing from DNA. That is the fundamental difference. We believe that we can deliver an unprecedented stability of expression, durability of expression, which would enable less frequent dosing. We are now actively going around and discussing the data that we have with in vivo CAR companies. The aim would be to try and enter into research collaborations with such companies where we can test delivery of Circuit vectors to T cells, to the spleen, and compare directly with the technology of those companies. That would certainly be an aim to try and get a head-to-head benchmark with one or more of the in vivo CAR companies. I think that concludes what we received in terms of questions. Thank you all for the interest. We will sign out from Circio. We'll keep you posted on progress. We'll plan for another webcast update probably in November. Thanks again, and have a nice day.